Dasatinib in Polycythemia Vera

PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

August 25, 2010

Study Completion Date

August 27, 2010

Conditions
Polycythemia Vera
Interventions
DRUG

Dasatinib

Patients will receive a once-daily oral administration of dasatinib at a dose of 100 mg QD (two 50 mg tablets taken together each day) for the duration of the study with the modifications as indicated. If the platelet count remains above 600,000/microL or the spleen remains enlarged in the absence of leukopenia or other side effects, the dose of dasatinib may be escalated to 120 mg QD (two 50 mg tablets plus one 20 mg tablet taken together each day).

Trial Locations (4)

10021

Weill Cornell Medical College - New York Presbyterian Hospital, New York

10956

Hematology/Oncology Associates of Rockland, New City

30322

Emory Winship Cancer Institute, Atlanta

38138

The Jones Clinic, Germantown

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER